(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.

The three biggest winners today are BASILIX CERT, CELYAD ONCOLOGY, and NAPATECH.

Financial Asset	Price	Change	Updated (EST)
BASILIX CERT (BAS.BR)	23.00	123.3%	2024-07-24 12:05:17
CELYAD ONCOLOGY (CYAD.BR)	0.27	5.88%	2024-07-24 12:05:50
NAPATECH (NAPA.OL)	39.50	5.61%	2024-07-24 12:41:21
BENEVOLENTAI (BAI.AS)	0.75	5.06%	2024-07-24 12:00:56
VEON (VEON.AS)	0.97	4.98%	2024-07-24 12:04:38
BIOTALYS (BTLS.BR)	2.98	4.56%	2024-07-24 12:05:37
SEABIRD EXPLORAT (SBX.OL)	5.29	3.93%	2024-07-24 12:43:06
MARTIFER (MAR.LS)	1.64	3.8%	2024-07-24 12:23:47
FOUNTAIN (FOU.BR)	1.45	3.57%	2024-07-24 12:06:35
BERGENBIO (BGBIO.OL)	13.02	3.53%	2024-07-24 12:25:18

The three biggest losers today are SEQUANA MEDICAL, INTEROIL EXPL PROD, and AUGROS COSMETICS.

Financial Asset	Price	Change	Updated (EST)
SEQUANA MEDICAL (SEQUA.BR)	0.80	-19.19%	2024-07-24 12:21:28
INTEROIL EXPL PROD (IOX.OL)	3.57	-12.92%	2024-07-24 12:40:39
AUGROS COSMETICS (AUGR.PA)	5.40	-10%	2024-07-24 12:46:16
KEYWARE TECH. (KEYW.BR)	0.74	-8.64%	2024-07-24 12:20:33
SPORTING (SCP.LS)	0.87	-7.49%	2024-07-24 12:24:11
VIVORYON (VVY.AS)	2.45	-6.17%	2024-07-24 12:04:41
BE SEMICONDUCTOR (BESI.AS)	144.70	-5.86%	2024-07-24 12:00:54
AMPLITUDE SURGICAL (AMPLI.PA)	2.92	-5.81%	2024-07-24 12:45:50
VAA VISTA ALEGRE (VAF.LS)	1.04	-4.59%	2024-07-24 12:24:18
KPN KON (KPN.AS)	3.63	-3.79%	2024-07-24 12:02:51

Winners today

1. BASILIX CERT (BAS.BR)

123.3% Price Change

Basilix Cert owns and operates a shopping center in Belgium. The company operates accessories, feed, beauty, jewelry, fashion, multimedia, and house shops, as well as restaurants. It offers products of approximately 40 brands. The company was founded in 1984 and is based in Brussels, Belgium. Basilix Cert is a subsidiary of KBC Bank NV. Basilix Cert operates as a subsidiary of KBC Bank NV.

BEL 20 ended the session with BASILIX CERT jumping 123.3% to €23.00 on Wednesday, after five consecutive sessions in a row of losses. BEL 20 rose 0.22% to €4,047.18, after two consecutive sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, BASILIX CERT has a trailing twelve months EPS of €-0.52.

Volume

Today’s last reported volume for BASILIX CERT is 625 which is 5581.82% above its average volume of 11.

More news about BASILIX CERT.

2. CELYAD ONCOLOGY (CYAD.BR)

5.88% Price Change

Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery/PerkinElmer for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

BEL 20 ended the session with CELYAD ONCOLOGY rising 5.88% to €0.27 on Wednesday, after three successive sessions in a row of losses. BEL 20 rose 0.22% to €4,047.18, after two successive sessions in a row of gains, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, CELYAD ONCOLOGY has a trailing twelve months EPS of €-1.36.

Volume

Today’s last reported volume for CELYAD ONCOLOGY is 4666 which is 69.26% below its average volume of 15179.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CELYAD ONCOLOGY’s stock is considered to be overbought (>=80).

Volatility

CELYAD ONCOLOGY’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.93%, a negative 0.69%, and a positive 2.90%.

CELYAD ONCOLOGY’s highest amplitude of average volatility was 1.97% (last week), 3.27% (last month), and 2.90% (last quarter).

More news about CELYAD ONCOLOGY.

3. NAPATECH (NAPA.OL)

5.61% Price Change

Napatech A/S offers reconfigurable computing solutions for the networking and cybersecurity applications worldwide. The company provides Link Capture Software that enables packet capture with nanosecond timestamping and replay with precise inter-frame gap control; Link Inline Software, which offers a processing architecture that offloads and accelerates flow aware application data planes; Link Virtualization Software that offloads and accelerates the Open vSwitch data plane to enhance CPU efficiency and network performance; and Link Programmable, which enables end users and OEMs to deploy FPGA computation solutions. It offers solutions for telecom operators, cloud and data center service providers, and infrastructure and defense, as well as financial services, cyber security, network management, and virtualization. Napatech A/S was incorporated in 2003 and is based in Copenhagen, Denmark.

Oslo Børs Benchmark Index_GI ended the session with NAPATECH rising 5.61% to €39.50 on Wednesday while Oslo Børs Benchmark Index_GI fell 0.46% to €1,440.21.

Earnings Per Share

As for profitability, NAPATECH has a trailing twelve months EPS of kr-0.73.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -56.66%.

Moving Average

NAPATECH’s value is way above its 50-day moving average of kr34.51 and way above its 200-day moving average of kr20.70.

Volume

Today’s last reported volume for NAPATECH is 87811 which is 76.35% below its average volume of 371363.

More news about NAPATECH.

4. BENEVOLENTAI (BAI.AS)

5.06% Price Change

BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company's development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the potential treatment of ALS; and various candidates for the treatment of fibrosis and Parkinson's disease. It has collaboration agreements with AstraZeneca and Merck to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

AEX-Index ended the session with BENEVOLENTAI rising 5.06% to €0.75 on Wednesday, following the last session’s upward trend. AEX-Index fell 1.26% to €903.46, following the last session’s downward trend on what was an all-around bearish trend exchanging session today.

Earnings Per Share

As for profitability, BENEVOLENTAI has a trailing twelve months EPS of €-0.64.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -51.01%.

More news about BENEVOLENTAI.

5. VEON (VEON.AS)

4.98% Price Change

VEON Ltd., a digital operator, provides connectivity and internet services in Pakistan, Ukraine, Kazakhstan, Bangladesh, Uzbekistan, and Kyrgyzstan. It offers mobile telecommunications services, including value added and call completion, national and international roaming, wireless Internet access, mobile financial, and mobile bundle services; data connectivity, cross border transit, voice, Internet, and data services; fixed-line telecommunications using intercity fiber optic networks; and Internet-TV using Fiber to the building technology. The company also sells equipment, infrastructure, and accessories. VEON Ltd. was founded in 1992 and is headquartered in Amsterdam, the Netherlands.

AEX-Index ended the session with VEON jumping 4.98% to €0.97 on Wednesday while AEX-Index dropped 1.26% to €903.46.

Earnings Per Share

As for profitability, VEON has a trailing twelve months EPS of €0.16.

PE Ratio

VEON has a trailing twelve months price to earnings ratio of 6.06. Meaning, the purchaser of the share is investing €6.06 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 43.63%.

Moving Average

VEON’s value is higher than its 50-day moving average of €0.95 and way higher than its 200-day moving average of €0.81.

More news about VEON.

6. BIOTALYS (BTLS.BR)

4.56% Price Change

Biotalys NV, an agricultural technology company, discovers and develops novel biological products in Belgium and internationally. The company offers biofungicides and bioinsecticides. It also develops EVOCA 1st generation, EVOCA Next generation, and BIOFUN-6 targeting botrytis, powdery mildew, and anthracnose in fruits and vegetables; BIOFUN-7 targeting leafspot disease in cowpeas and other legumes; and BIOFUN-4 targeting oomycetes in fruits and vegetables. The company was formerly known as Agrosavfe NV. Biotalys NV was incorporated in 2013 and is headquartered in Gent, Belgium.

BEL 20 ended the session with BIOTALYS rising 4.56% to €2.98 on Wednesday while BEL 20 jumped 0.22% to €4,047.18.

Earnings Per Share

As for profitability, BIOTALYS has a trailing twelve months EPS of €-0.65.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOTALYS’s stock is considered to be oversold (<=20).

More news about BIOTALYS.

7. SEABIRD EXPLORAT (SBX.OL)

3.93% Price Change

SeaBird Exploration Plc, together with its subsidiaries, provides marine seismic data for the oil and gas industry in Europe, Africa, the Middle East, North and South America, and the Asia Pacific. It offers 2D seismic; and source vessels that provide conventional undershoot, 4D repeat survey, wide azimuth, push reverse, long-term charter and vessel management, in-house source modelling and environmental decay analysis, and spot charter services. The company was founded in 1996 and is based in Nicosia, Cyprus.

Oslo Børs Benchmark Index_GI ended the session with SEABIRD EXPLORAT jumping 3.93% to €5.29 on Wednesday, after two successive sessions in a row of gains. Oslo Børs Benchmark Index_GI dropped 0.46% to €1,440.21, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, SEABIRD EXPLORAT has a trailing twelve months EPS of kr-0.22.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -3.82%.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Jun 10, 2024, the estimated forward annual dividend rate is 0.25 and the estimated forward annual dividend yield is 5.13%.

Volume

Today’s last reported volume for SEABIRD EXPLORAT is 311912 which is 50.4% above its average volume of 207376.

Moving Average

SEABIRD EXPLORAT’s value is higher than its 50-day moving average of kr4.83 and way above its 200-day moving average of kr4.78.

More news about SEABIRD EXPLORAT.

8. MARTIFER (MAR.LS)

3.8% Price Change

Martifer SGPS, S.A. operates in the metallic constructions and renewable energy development sectors worldwide. It operates through Metallic Constructions, Naval Industry, and Renewables segments. The Metallic Constructions segment engages in the construction activities involving metal mechanical construction, aluminum, and glass façades, as well as infrastructures for oil and gas. The Naval Industry segment involved in shipbuilding, as well as provides ship repair services. The Renewables segment engages in the development, licensing, building, and operating of renewable energy projects, including wind and solar power projects. The company was founded in 1990 and is headquartered in Oliveira de Frades, Portugal.

PSI ended the session with MARTIFER rising 3.8% to €1.64 on Wednesday, after two successive sessions in a row of losses. PSI jumped 0.65% to €6,898.82, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, MARTIFER has a trailing twelve months EPS of €0.2.

PE Ratio

MARTIFER has a trailing twelve months price to earnings ratio of 8.2. Meaning, the purchaser of the share is investing €8.2 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 53.03%.

Volatility

MARTIFER’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.56%, a negative 0.21%, and a positive 1.42%.

MARTIFER’s highest amplitude of average volatility was 1.35% (last week), 1.30% (last month), and 1.42% (last quarter).

More news about MARTIFER.

9. FOUNTAIN (FOU.BR)

3.57% Price Change

Fountain S.A. engages in the sale, rental, and provision of machines for cold and hot drinks made from freeze-dried or grain products in in France, Belgium, the Netherlands, and rest of European Countries. It provides coffee and cartridge machines, and other beverages machines. The company offers its products through independent distributors. Fountain S.A. was incorporated in 1972 and is based in Braine l'Alleud, Belgium.

BEL 20 ended the session with FOUNTAIN rising 3.57% to €1.45 on Wednesday while BEL 20 rose 0.22% to €4,047.18.

Earnings Per Share

As for profitability, FOUNTAIN has a trailing twelve months EPS of €0.18.

PE Ratio

FOUNTAIN has a trailing twelve months price to earnings ratio of 8.06. Meaning, the purchaser of the share is investing €8.06 for every euro of annual earnings.

Volatility

FOUNTAIN’s last week, last month’s, and last quarter’s current intraday variation average was 7.69%, 0.46%, and 4.13%.

FOUNTAIN’s highest amplitude of average volatility was 7.69% (last week), 5.88% (last month), and 4.13% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FOUNTAIN’s stock is considered to be oversold (<=20).

Volume

Today’s last reported volume for FOUNTAIN is 710 which is 43.06% below its average volume of 1247.

More news about FOUNTAIN.

10. BERGENBIO (BGBIO.OL)

3.53% Price Change

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company's lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute respiratory distress syndrome; Tilvestamab (BGB149), anti-AXL monoclonal antibody, which in phase 1 clinical trial for the treatment of ovarian cancer; and Mipasetamab Uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. BerGenBio ASA was incorporated in 2007 and is based in Bergen, Norway.

Oslo Børs Benchmark Index_GI ended the session with BERGENBIO rising 3.53% to €13.02 on Wednesday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI dropped 0.46% to €1,440.21, following the last session’s downward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, BERGENBIO has a trailing twelve months EPS of kr67.

PE Ratio

BERGENBIO has a trailing twelve months price to earnings ratio of 0.19. Meaning, the purchaser of the share is investing kr0.19 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -179.58%.

More news about BERGENBIO.

Losers Today

1. SEQUANA MEDICAL (SEQUA.BR)

-19.19% Price Change

Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, Switzerland, and internationally. The company products pipeline comprises alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body and heart failure. Sequana Medical NV was founded in 2006 and is headquartered in Ghent, Belgium.

BEL 20 ended the session with SEQUANA MEDICAL sliding 19.19% to €0.80 on Wednesday, after three consecutive sessions in a row of losses. BEL 20 rose 0.22% to €4,047.18, after two successive sessions in a row of gains, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, SEQUANA MEDICAL has a trailing twelve months EPS of €-1.22.

Volume

Today’s last reported volume for SEQUANA MEDICAL is 239157 which is 559.14% above its average volume of 36283.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SEQUANA MEDICAL’s stock is considered to be overbought (>=80).

Yearly Top and Bottom Value

SEQUANA MEDICAL’s stock is valued at €0.80 at 22:40 EST, way below its 52-week low of €1.13.

More news about SEQUANA MEDICAL.

2. INTEROIL EXPL PROD (IOX.OL)

-12.92% Price Change

Interoil Exploration and Production ASA, together with its subsidiaries, operates as an upstream oil exploration and production company in Argentina and Colombia. It engages in the acquisition, exploration, development, and operation of oil and natural gas properties. The company's portfolio includes two producing concessions and two exploration concessions in Colombia; and one exploration and seven production concessions in Argentina. Interoil Exploration and Production ASA was incorporated in 2005 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with INTEROIL EXPL PROD sliding 12.92% to €3.57 on Wednesday while Oslo Børs Benchmark Index_GI slid 0.46% to €1,440.21.

Earnings Per Share

As for profitability, INTEROIL EXPL PROD has a trailing twelve months EPS of kr0.03.

PE Ratio

INTEROIL EXPL PROD has a trailing twelve months price to earnings ratio of 119. Meaning, the purchaser of the share is investing kr119 for every norwegian krone of annual earnings.

Revenue Growth

Year-on-year quarterly revenue growth grew by 206.4%, now sitting on 24.45M for the twelve trailing months.

Moving Average

INTEROIL EXPL PROD’s value is way below its 50-day moving average of kr5.35 and way below its 200-day moving average of kr4.92.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, INTEROIL EXPL PROD’s stock is considered to be overbought (>=80).

Volume

Today’s last reported volume for INTEROIL EXPL PROD is 299720 which is 36.11% below its average volume of 469162.

More news about INTEROIL EXPL PROD.

3. AUGROS COSMETICS (AUGR.PA)

-10% Price Change

Augros Cosmetic Packaging SA provides customized packaging solutions in France. The company offers decoration solutions for glass, plastic, and aluminum packaging materials. It serves the perfume, cosmetic, and spirit industries. The company is based in Alençon, France. Augros Cosmetic Packaging SA operates as a subsidiary of Famille Bourgine.

CAC 40 ended the session with AUGROS COSMETICS falling 10% to €5.40 on Wednesday, after four successive sessions in a row of losses. CAC 40 slid 1.12% to €7,513.73, following the last session’s downward trend on what was an all-around down trend trading session today.

Earnings Per Share

As for profitability, AUGROS COSMETICS has a trailing twelve months EPS of €-0.54.

Volume

Today’s last reported volume for AUGROS COSMETICS is 143 which is 101.4% above its average volume of 71.

More news about AUGROS COSMETICS.

4. KEYWARE TECH. (KEYW.BR)

-8.64% Price Change

Keyware Technologies NV, an independent fintech company, provides electronic payments processing and management solutions in Belgium. It offers payment transaction software for banks and financial institutions, tokenization software, instalment payment solutions, and payment processing and management services, as well as rents and sells payment terminals. The company was incorporated in 1996 and is headquartered in Zaventem, Belgium.

BEL 20 ended the session with KEYWARE TECH. dropping 8.64% to €0.74 on Wednesday while BEL 20 rose 0.22% to €4,047.18.

Earnings Per Share

As for profitability, KEYWARE TECH. has a trailing twelve months EPS of €0.01.

PE Ratio

KEYWARE TECH. has a trailing twelve months price to earnings ratio of 74. Meaning, the purchaser of the share is investing €74 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.98%.

More news about KEYWARE TECH..

5. SPORTING (SCP.LS)

-7.49% Price Change

Sporting Clube de Portugal – Futebol, SAD operates sports clubs in Portugal. The company also engages in the sale of tickets for games; advertising and sponsorships activities; and provision of television rights. Sporting Clube de Portugal – Futebol, SAD was founded in 1907 and is headquartered in Lisbon, Portugal.

PSI ended the session with SPORTING sliding 7.49% to €0.87 on Wednesday, following the last session’s downward trend. PSI rose 0.65% to €6,898.82, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, SPORTING has a trailing twelve months EPS of €0.18.

PE Ratio

SPORTING has a trailing twelve months price to earnings ratio of 4.81. Meaning, the purchaser of the share is investing €4.81 for every euro of annual earnings.

Revenue Growth

Year-on-year quarterly revenue growth grew by 19.5%, now sitting on 118.31M for the twelve trailing months.

More news about SPORTING.

6. VIVORYON (VVY.AS)

-6.17% Price Change

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.

AEX-Index ended the session with VIVORYON dropping 6.17% to €2.45 on Wednesday, following the last session’s downward trend. AEX-Index fell 1.26% to €903.46, following the last session’s downward trend on what was an all-around bearish trend exchanging session today.

Earnings Per Share

As for profitability, VIVORYON has a trailing twelve months EPS of €-1.12.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -107.38%.

More news about VIVORYON.

7. BE SEMICONDUCTOR (BESI.AS)

-5.86% Price Change

BE Semiconductor Industries N.V. engages in the development, manufacture, marketing, sale, and service of semiconductor assembly equipment for the semiconductor and electronics industries in China, the United States, Malaysia, Ireland, Korea, Taiwan, Thailand, Other Asia Pacific and Europe, and internationally. It operates through three segments: Die Attach, Packaging, and Plating. The company's principal products include die attach equipment, such as single chip, multi-chip, multi module, flip chip, thermal compression bonding, fan out wafer level packaging, hybrid and embedded bridge die bonding, and die sorting systems; and packaging equipment, including conventional, ultra-thin, and wafer level molding, as well as trim and form, and singulation systems. It also provides plating equipment, such as tin, copper, and precious metal and solar plating systems, as well as related process chemicals; and tooling, conversion kits, spare parts, and other services. The company's principal brand names include Datacon, Esec, Fico, and Meco. It offers its products primarily to multinational chip manufacturers, assembly subcontractors, and electronics and industrial companies. BE Semiconductor Industries N.V. was incorporated in 1995 and is headquartered in Duiven, the Netherlands.

AEX-Index ended the session with BE SEMICONDUCTOR sliding 5.86% to €144.70 on Wednesday, after two consecutive sessions in a row of gains. AEX-Index fell 1.26% to €903.46, following the last session’s downward trend on what was an all-around down trend trading session today.

Earnings Per Share

As for profitability, BE SEMICONDUCTOR has a trailing twelve months EPS of €2.23.

PE Ratio

BE SEMICONDUCTOR has a trailing twelve months price to earnings ratio of 64.89. Meaning, the purchaser of the share is investing €64.89 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.81%.

Sales Growth

BE SEMICONDUCTOR’s sales growth is negative 5.8% for the present quarter and 47.8% for the next.

Yearly Top and Bottom Value

BE SEMICONDUCTOR’s stock is valued at €144.70 at 22:40 EST, way under its 52-week high of €182.90 and way above its 52-week low of €84.16.

Moving Average

BE SEMICONDUCTOR’s value is below its 50-day moving average of €150.24 and above its 200-day moving average of €137.89.

Volume

Today’s last reported volume for BE SEMICONDUCTOR is 329349 which is 15.55% below its average volume of 390034.

More news about BE SEMICONDUCTOR.

8. AMPLITUDE SURGICAL (AMPLI.PA)

-5.81% Price Change

Amplitude Surgical SA develops and markets products for orthopedic surgery. The company provides a range of orthopedic products for primary and revision surgery aimed at treating pathologies of the hip, knee, and lower extremities primarily for foot and ankle surgery. It also offers AMPLIVISION, a computer-assisted surgical system; the i.M.A.G.E., a single-use made-to-measure instrument system; and E.T.O.I.L.E, a technology platform for anterior approaches resulting in less-invasive surgery. In addition, the company provides instruments for fitting related accessories. It sells its products through a network of distributors and agents in approximately 30 countries. The company serves patients, surgeons, and healthcare facilities. Amplitude Surgical SA was founded in 1997 and is headquartered in Valence, France. As of January 21, 2021, Amplitude Surgical SA operates as a subsidiary of PAI Partners.

CAC 40 ended the session with AMPLITUDE SURGICAL falling 5.81% to €2.92 on Wednesday while CAC 40 dropped 1.12% to €7,513.73.

Earnings Per Share

As for profitability, AMPLITUDE SURGICAL has a trailing twelve months EPS of €-0.06.

Volatility

AMPLITUDE SURGICAL’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.38%, a negative 0.38%, and a positive 2.04%.

AMPLITUDE SURGICAL’s highest amplitude of average volatility was 3.38% (last week), 2.03% (last month), and 2.04% (last quarter).

More news about AMPLITUDE SURGICAL.

9. VAA VISTA ALEGRE (VAF.LS)

-4.59% Price Change

Vista Alegre Atlantis, SGPS, S.A. produces, distributes, and sells porcelain tableware, decorative and giftware; tableware, barware, decanters, candlesticks/tea lights, glass sets, and desk accessories. It also provides stainless steel cutlery products. In addition, the company offers lighting products. It provides its products through independent retailers, distributors, online as well as through its own retail network under the Vista Alegre brand name. Vista Alegre Atlantis, SGPS, S.A. was founded in 1980 and is headquartered in Ílhavo, Portugal. Vista Alegre Atlantis, SGPS, S.A. is a subsidiary of Visabeira Indústria SGPS, S.A.

PSI ended the session with VAA VISTA ALEGRE sliding 4.59% to €1.04 on Wednesday while PSI rose 0.65% to €6,898.82.

Earnings Per Share

As for profitability, VAA VISTA ALEGRE has a trailing twelve months EPS of €0.04.

PE Ratio

VAA VISTA ALEGRE has a trailing twelve months price to earnings ratio of 26. Meaning, the purchaser of the share is investing €26 for every euro of annual earnings.

Revenue Growth

Year-on-year quarterly revenue growth declined by 11.8%, now sitting on 139.75M for the twelve trailing months.

Moving Average

VAA VISTA ALEGRE’s value is way higher than its 50-day moving average of €0.78 and way above its 200-day moving average of €0.81.

More news about VAA VISTA ALEGRE.

10. KPN KON (KPN.AS)

-3.79% Price Change

Koninklijke KPN N.V. provides telecommunications and information technology (IT) services in the Netherlands. It operates through Consumer; Business; Wholesale; and Network, Operations & IT segments. The company offers fixed and mobile telephony, fixed and mobile broadband internet, and television services to retail and business consumers; infrastructure and network related IT solutions to business customers; and wholesale network services to third parties. It also provides IT services, including cloud, workspace, and cybersecurity services; interconnect traffic, visitor roaming, and digital products; and NL-ix, an interconnect exchange, as well as sells handsets, peripheral equipment, and software licenses. In addition, the company offers virus and malware scanners; anti-virus licenses; 1Password, a password management tool; DNSSEC, a technology that prevents customers from being led to fake websites; KPN Veilig Netwerk Thuis, a smart network security; Censornet, which includes web security, cloud application security broker, email protection, and awareness training; SuperVision, which provides digital governance solutions for workspaces; and OneMonitoring to ensure early detection of cyber incidents. Further, it provides fiber networks; and IT services for integrating healthcare systems and optimizing communication between healthcare providers. The company distributes its products and services under the KPN, XS4ALL, Simyo, KPN Security, KPN Health, Solcon, Inspark, and KPN Partner Network brands. The company was formerly known as Koninklijke PTT Nederland NV and changed its name to Koninklijke KPN N.V. in June 1998. Koninklijke KPN N.V. was founded in 1881 and is headquartered in Rotterdam, the Netherlands.

AEX-Index ended the session with KPN KON sliding 3.79% to €3.63 on Wednesday while AEX-Index fell 1.26% to €903.46.

Earnings Per Share

As for profitability, KPN KON has a trailing twelve months EPS of €0.21.

PE Ratio

KPN KON has a trailing twelve months price to earnings ratio of 17.27. Meaning, the purchaser of the share is investing €17.27 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.12%.

Sales Growth

KPN KON’s sales growth is 2.5% for the present quarter and 2.8% for the next.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Apr 19, 2024, the estimated forward annual dividend rate is 0.15 and the estimated forward annual dividend yield is 3.99%.

More news about KPN KON.

Stay up to date with our winners and losers daily report